Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | Tofacitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IFN-a2 | 62.0 | 55 | |
RA2159 | IKK16 | 2.0 | uM | Adiponectin | 5 | ng/mL | 3 | IFN-a2 | 62.5 | 54 | |
N2586 | Adiponectin | 5 | ng/mL | 3 | IFN-a2 | 96.0 | 73 | ||||
N2586 | PD184352 | 0.1 | uM | Adiponectin | 5 | ng/mL | 3 | IFN-a2 | 102.0 | 75 | |
N2586 | Lestaurtinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IFN-a2 | 89.0 | 55 | |
N2586 | Ruxolitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IFN-a2 | 92.0 | 57 | |
N2586 | Tofacitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IFN-a2 | 89.5 | 52 | |
N2586 | IKK16 | 2.0 | uM | Adiponectin | 5 | ng/mL | 3 | IFN-a2 | 94.0 | 66 | |
RA2159 | IGF-I | 100 | ug/mL | 3 | IFN-a2 | 21.0 | 56 | ||||
RA2159 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | IFN-a2 | 23.0 | 59 | |
RA2159 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IFN-a2 | 20.0 | 70 | |
RA2159 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IFN-a2 | 19.0 | 63 | |
RA2159 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IFN-a2 | 20.0 | 67 | |
RA2159 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | IFN-a2 | 22.0 | 52 | |
RA2159 | 3 | IFN-a2 | 21.0 | 56 | |||||||
N2586 | IGF-I | 100 | ug/mL | 3 | IFN-a2 | 64.0 | 63 | ||||
N2586 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | IFN-a2 | 65.0 | 50 | |
N2586 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IFN-a2 | 43.5 | 52 | |
N2586 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IFN-a2 | 62.0 | 46 | |
N2586 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IFN-a2 | 36.0 | 67 | |
N2586 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | IFN-a2 | 42.0 | 80 | |
N2586 | 3 | IFN-a2 | 47.0 | 61 | |||||||
RA2159 | EGF | 100 | ng/mL | 3 | IFN-a2 | 20.5 | 52 | ||||
RA2159 | PD184352 | 0.1 | uM | EGF | 100 | ng/mL | 3 | IFN-a2 | 21.0 | 77 | |
RA2159 | Lestaurtinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IFN-a2 | 20.5 | 72 |